1-19 of 19
Katherine S. Panageas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma

Ankush Bhatia, Raquel Moreno, Anne S. Reiner, Subhiksha Nandakumar, Henry S. Walch, Teena M. Thomas, Philip J. Nicklin, Ye Choi, Anna Skakodub, Rachna Malani, Vivek Prabhakaran, Pallavi Tiwari, Maria Diaz, Katherine S. Panageas, Ingo K. Mellinghoff, Tejus A. Bale, Robert J. Young
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1180
Published: 01 November 2023
View article titled, Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Open the PDF for Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma in another window
Includes: Supplementary data
Journal Articles

The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer

Noura J. Choudhury, Jessica A. Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc Tran, Hira Rizvi, Kathryn C. Arbour, Karissa Whiting, Ronglai Shen, Matthew Hellmann, Philippe L. Bedard, Celeste Yu, Natasha Leighl, Michele LeNoue-Newton, Christine Micheel, Jeremy L. Warner, Michelle S. Ginsberg, Andrew Plodkowski, Jeffrey Girshman, Peter Sawan, Shirin Pillai, Shawn M. Sweeney, Kenneth L. Kehl, Katherine S. Panageas, Nikolaus Schultz, Deborah Schrag, Gregory J. Riely, on behalf of the AACR GENIE BPC Core Team
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3418–3428.
https://doi.org/10.1158/1078-0432.CCR-23-0580
Published: 01 September 2023
View article titled, The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Open the PDF for The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Alexander N. Shoushtari, Walid K. Chatila, Arshi Arora, Francisco Sanchez-Vega, Havish S. Kantheti, Jorge A. Rojas Zamalloa, Penina Krieger, Margaret K. Callahan, Allison Betof Warner, Michael A. Postow, Parisa Momtaz, Suresh Nair, Charlotte E. Ariyan, Christopher A. Barker, Mary Susan Brady, Daniel G. Coit, Neal Rosen, Paul B. Chapman, Klaus J. Busam, David B. Solit, Katherine S. Panageas, Jedd D. Wolchok, Nikolaus Schultz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-20-4189
Published: 15 April 2021
View article titled, Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Open the PDF for Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas in another window
Includes: Supplementary data
Journal Articles

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Michael A. Postow, Susan J. Knox, Debra A. Goldman, Yuval Elhanati, Vikram Mavinkurve, Phillip Wong, Darragh Halpenny, Sunil K. Reddy, Kenya Vado, Danielle McCabe, Kristen Aufiero Ramirez, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Parisa Momtaz, Alexander N. Shoushtari, Margaret K. Callahan, Paul B. Chapman, Jedd D. Wolchok, Priyanka B. Subrahmanyam, Holden T. Maecker, Katherine S. Panageas, Christopher A. Barker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3193–3201.
https://doi.org/10.1158/1078-0432.CCR-19-3936
Published: 01 July 2020
View article titled, A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Open the PDF for A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research

Kelley M. Kidwell, Michael A. Postow, Katherine S. Panageas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 730–736.
https://doi.org/10.1158/1078-0432.CCR-17-1355
Published: 14 February 2018
View article titled, Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research
Open the PDF for Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research in another window
Journal Articles

Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

Antonio Omuro, Kathryn Beal, Philip Gutin, Sasan Karimi, Denise D. Correa, Thomas J. Kaley, Lisa M. DeAngelis, Timothy A. Chan, Igor T. Gavrilovic, Craig Nolan, Adilia Hormigo, Andrew B. Lassman, Ingo Mellinghoff, Christian Grommes, Anne S. Reiner, Katherine S. Panageas, Raymond E. Baser, Viviane Tabar, Elena Pentsova, Juan Sanchez, Renata Barradas-Panchal, Jianan Zhang, Geraldine Faivre, Cameron W. Brennan, Lauren E. Abrey, Jason T. Huse
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (19): 5023–5031.
https://doi.org/10.1158/1078-0432.CCR-14-0822
Published: 30 September 2014
View article titled, Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Open the PDF for Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2257–2264.
https://doi.org/10.1158/1078-0432.CCR-12-3476
Published: 15 April 2013
View article titled, Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Open the PDF for Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma in another window
Includes: Supplementary data
Journal Articles

Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

Emanuela Romano, Marco Rossi, Gudrun Ratzinger, Maria-Angeles de Cos, David J. Chung, Katherine S. Panageas, Jedd D. Wolchock, Alan N. Houghton, Paul B. Chapman, Glenn Heller, Jianda Yuan, James W. Young
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1984–1997.
https://doi.org/10.1158/1078-0432.CCR-10-3421
Published: 31 March 2011
View article titled, Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em>
Open the PDF for Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

Todd L. Rosenblat, Michael R. McDevitt, Deborah A. Mulford, Neeta Pandit-Taskar, Chaitanya R. Divgi, Katherine S. Panageas, Mark L. Heaney, Suzanne Chanel, Alfred Morgenstern, George Sgouros, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5303–5311.
https://doi.org/10.1158/1078-0432.CCR-10-0382
Published: 31 October 2010
View article titled, Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
Open the PDF for Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia in another window
Journal Articles

Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection

Brian A. Ginsberg, Humilidad F. Gallardo, Teresa S. Rasalan, Matthew Adamow, Zhenyu Mu, Sapna Tandon, Barrett B. Bewkes, Ruth-Ann Roman, Paul B. Chapman, Gary K. Schwartz, Richard D. Carvajal, Katherine S. Panageas, Stephanie L. Terzulli, Alan N. Houghton, Jianda D. Yuan, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 4057–4065.
https://doi.org/10.1158/1078-0432.CCR-10-1093
Published: 28 July 2010
View article titled, Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection
Open the PDF for Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection in another window
Journal Articles

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

David B. Solit, Iman Osman, David Polsky, Katherine S. Panageas, Adil Daud, James S. Goydos, Jerrold Teitcher, Jedd D. Wolchok, F. Joseph Germino, Susan E. Krown, Daniel Coit, Neal Rosen, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8302–8307.
https://doi.org/10.1158/1078-0432.CCR-08-1002
Published: 15 December 2008
View article titled, Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
Open the PDF for Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Maura N. Dickler, Hope S. Rugo, Carey A. Eberle, Edi Brogi, James F. Caravelli, Katherine S. Panageas, Jeff Boyd, Benjamin Yeh, Diana E. Lake, Chau T. Dang, Teresa A. Gilewski, Jacqueline F. Bromberg, Andrew D. Seidman, Gabriella M. D'Andrea, Mark M. Moasser, Michele Melisko, John W. Park, Janet Dancey, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7878–7883.
https://doi.org/10.1158/1078-0432.CCR-08-0141
Published: 01 December 2008
View article titled, A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
Open the PDF for A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer

Monica N. Fornier, Andrew D. Seidman, Diana Lake, Gabriella D'Andrea, Jacqueline Bromberg, Mark Robson, Catherine Van Poznak, Katherine S. Panageas, Marietta Atienza, Larry Norton, Clifford Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (1): 223–227.
https://doi.org/10.1158/1078-0432.CCR-06-1731
Published: 02 January 2007
View article titled, Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Open the PDF for Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer in another window
Journal Articles

YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

Adília Hormigo, Bin Gu, Sasan Karimi, Elyn Riedel, Katherine S. Panageas, Mark A. Edgar, Meena K. Tanwar, Jasti S. Rao, Martin Fleisher, Lisa M. DeAngelis, Eric C. Holland
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5698–5704.
https://doi.org/10.1158/1078-0432.CCR-06-0181
Published: 04 October 2006
View article titled, YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas
Open the PDF for YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas in another window
Journal Articles

PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation

Maryann Mikhail, Elsa Velazquez, Richard Shapiro, Russell Berman, Anna Pavlick, Lian Sorhaindo, Joanna Spira, Carmen Mir, Katherine S. Panageas, David Polsky, Iman Osman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (14): 5153–5157.
https://doi.org/10.1158/1078-0432.CCR-05-0397
Published: 20 July 2005
View article titled, PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation
Open the PDF for PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation in another window
Journal Articles

Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer

Chau T. Dang, Gabriella M. D’Andrea, Mary E. Moynahan, Maura N. Dickler, Andrew D. Seidman, Monica Fornier, Mark E. Robson, Maria Theodoulou, Diana Lake, Violante E. Currie, Arti Hurria, Katherine S. Panageas, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (17): 5754–5761.
https://doi.org/10.1158/1078-0432.CCR-04-0634
Published: 08 September 2004
View article titled, Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Open the PDF for Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer in another window
Journal Articles

Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments

Chau T. Dang, Andrew J. Dannenberg, Kotha Subbaramaiah, Maura N. Dickler, Mark M. Moasser, Andrew D. Seidman, Gabriella M. D’Andrea, Maria Theodoulou, Katherine S. Panageas, Larry Norton, Clifford A. Hudis
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (12): 4062–4067.
https://doi.org/10.1158/1078-0432.CCR-03-0463
Published: 24 June 2004
View article titled, Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
Open the PDF for Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments in another window
Journal Articles

T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants

Susanne G. Schaed, Virginia M. Klimek, Katherine S. Panageas, Cristina M. Musselli, Leah Butterworth, Wen-Jen Hwu, Philip O. Livingston, Linda Williams, Jonathan J. Lewis, Alan N. Houghton, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (5): 967–972.
Published: 01 May 2002
View article titled, T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle>
Open the PDF for T-Cell Responses against Tyrosinase 368–376(370D) Peptide in HLA∗A0201<sup>+</sup> Melanoma Patients: <subtitle>Randomized Trial Comparing Incomplete Freund’s Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants</subtitle> in another window
Journal Articles

Vaccination with a Bivalent GM2 and GD2 Ganglioside Conjugate Vaccine: A Trial Comparing Doses of GD2-Keyhole Limpet Hemocyanin

Paul B. Chapman, Donna Morrisey, Katherine S. Panageas, Linda Williams, Jonathan J. Lewis, Robert J. Israel, W. Bradley Hamilton, Philip O. Livingston
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (12): 4658–4662.
Published: 01 December 2000
View article titled, Vaccination with a Bivalent G<sub>M2</sub> and G<sub>D2</sub> Ganglioside Conjugate Vaccine: A Trial Comparing Doses of G<sub>D2</sub>-Keyhole Limpet Hemocyanin
Open the PDF for Vaccination with a Bivalent G<sub>M2</sub> and G<sub>D2</sub> Ganglioside Conjugate Vaccine: A Trial Comparing Doses of G<sub>D2</sub>-Keyhole Limpet Hemocyanin in another window